Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection
Author(s): Wu George, Powers Dan, Yeung Stanley, Chen Frank
Issue: Jan/Feb 2018 - Volume 22, Number 1
View All Articles in Issue
Page(s): 76-85
Download in electronic PDF format for $75
Abstract: Prophylaxis or therapy with a combination of a neurokinin 1 (NK-1) receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT3) RA, and dexamethasone is recommended by international antiemesis guidelines for the prevention of chemotherapy-induced nausea and vomiting for patients receiving highly emetogenic chemotherapy and for selected patients receiving moderately emetogenic chemotherapy. VARUBI (rolapitant) is a substance P/NK-1 RA that was recently approved by the U.S. Food and Drug Administration as an injectable emulsion in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Palonosetron is one of the 5-HT3 RAs indicated for the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Herein, we describe the physical and chemical compatibility and stability of VARUBI injectable emulsion (166.5 mg/92.5 mL [1.8 mg/mL, free base], equivalent to 185 mg of rolapitant hydrochloride) admixed with palonosetron injection 0.25 mg free base in 5 mL (equivalent to 0.28 mg hydrochloride salt) and with either 5 mL (20 mg) or 2.5 mL (10 mg) of dexamethasone sodium phosphate. Admixtures were prepared and stored in VARUBI injectable emulsion ready-to-use glass vials as supplied by the rolapitant manufacturer and in four types of commonly used intravenous administration (tubing) sets. Assessment of the physical and chemical compatibility and stability of the admixtures in the VARUBI ready-to-use vials stored at room temperature (20°C to 25°C) under fluorescent light and under refrigeration (2°C to 8°C protected from light) was conducted at 0, 1, 6, 24, and 48 hours, and that of the admixtures in the intravenous tubing sets was evaluated at 0, 2, and 6 hours of storage at 20°C to 25°C. Physical stability was evaluated by visual examination of the container contents under normal room light, and measurement of turbidity, globule size, and particulate matter. Chemical stability was assessed by measuring the pH of the admixture and determining drug concentrations (potency) and impurity levels by high-performance liquid chromatographic analysis. All samples were physically and chemically compatible throughout the study duration. The pH, turbidity, globule size, and particulate matter of the admixture stayed within narrow and acceptable ranges. VARUBI injectable emulsion admixed with intravenous palonosetron and dexamethasone was chemically and physically stable in the ready-to-use glass vials for at least 24 hours at room temperature and 48 hours under refrigeration, as well as in the four selected intravenous tubing sets for at least 6 hours at room temperature. No decrease of drug concentration (or potency) of any admixed components occurred in the samples stored at the two temperature ranges and time periods studied as measured by high-performance liquid chromatographic analysis
Related Keywords:
George Wu, PhD, Dan Powers, DO, Stanley Yeung, PharmD, Frank Chen, PhD, VARUBI, rolapitant, drug admixtures, neurokinin 1 receptor antagonist, 5-HT3 receptor antagonist, dexamethasone, chemotherapy-induced nausea and vomiting, emesis, antiemetic agent, palonosetron hydrochloride, substance P receptor antagonist, stability, injectable emulsion, triple combination therapy, intravenous tubing set compatibility, storage conditions
Related Categories:
CANCER AND AIDS, GASTROENTEROLOGY, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, ALLERGY/IMMUNOLOGY/INFLAMMATION, NEUROLOGY
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride
Wu George, Powers Dan, Yeung Stanley, Chen Frank, Neelon Kelly
|
Jan/Feb 2018
Pg. 86-94
|
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection
Wu George, Powers Dan, Yeung Stanley, Chen Frank
|
Jan/Feb 2018
Pg. 76-85
|
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride
Wu George, Yeung Stanley, Chen Frank
|
Jan/Feb 2017
Pg. 76-82
|
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate
Wu George, Yeung Stanley, Chen Frank
|
Jan/Feb 2017
Pg. 66-75
|
Rolapitant Injectable Emulsion with Dexamethasone Sodium Phosphate Admixture
Allen Loyd V Jr
|
May/Jun 2018
Pg. 237
|
Rolapitant Injectable Emulsion with Palonosetron Hydrochloride Admixture
Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 151
|
Compatibility and Stability of Aloxi (Palonosetron Hydrochloride) Admixed With Dexamethasone Sodium Phosphate
Trissel Lawrence A, Zhang Yanping
|
Sep/Oct 2004
Pg. 398-403
|
Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration
Ben Michel, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
|
Nov/Dec 2007
Pg. 520-524
|
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
|
Nov/Dec 2018
Pg. 516-526
|
Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration
Kupiec Thomas C, Ben Michel, Trusley Craig, Trissel Lawrence A
|
Mar/Apr 2008
Pg. 170-173
|
Compatibility and Stability of Palonosetron Hydrochloride and Propofol During Simulated Y-Site Administration
Trissel Lawrence A, Trusley Craig, Kupiec Thomas C, Ben Michel
|
Jan/Feb 2009
Pg. 78-80
|
Stability of Aminocaproic Acid Injection Admixtures in 5% Dextrose Injection and 0.9% Sodium Chloride Injection
Zhang Yan-ping, Trissel Lawrence A
|
Mar/Apr 1997
Pg. 132-134
|
Compatibility and Stability of Linezolid Injection Admixed with Gentamicin Sulfate and Tobramycin Sulfate
Xu Quanyun A, Trissel Lawrence A, Zhang Yanping, Williams Kimberly Y
|
Nov/Dec 2000
Pg. 476-479
|
Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration
Trusley Craig, Ben Michel, Kupiec Thomas C, Trissel Lawrence A
|
Mar/Apr 2008
Pg. 156-160
|
Stability of Diphenhydramine Hydrochloride, Lorazepam, and Dexamethasone Sodium Phosphate in 0.9% Sodium Chloride Stored in Polypropylene Syringes
Anderson Collin R, Halford Zachery, MacKay Mark
|
Jul/Aug 2015
Pg. 344-347
|
Dexamethasone Sodium Phosphate Ophthalmic Solution: Equivalent to 0.1% Dexamethasone Phosphate
Allen Loyd V Jr
|
Nov/Dec 2015
Pg. 508
|
Physical and Chemical Stability of Trepostinil Sodium Injection Packaged in Plastic Syringe Pump Reservoirs.
Xu Quanyun A, Trissel Lawrence A, Pham Lien
|
May/Jun 2004
Pg. 228-230
|
Intravenous Physical Compatibility of Heparin Sodium and Furosemide
Maktabi Briana, Howard Mitchell S, Baki Gabriella, Churchwell Mariann D
|
Nov/Dec 2022
Pg. 522-526
|
Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's, Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration
Ben Michel, Kupiec Thomas C, Trusley Craig, Trissel Lawrence A
|
Sep/Oct 2008
Pg. 460-462
|
Stability of Lidocaine Hydrochloride Injection at Ambient Temperature and 4°C in Polypropylene Syringes
Storms Meredith L, Stewart James T, Warren Flynn W
|
Sep/Oct 2002
Pg. 388-390
|
Return to Top |